Best Immunology Companies in China
The 61 best Immunology companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
China's Immunology sector has a funding story worth paying attention to: 61 companies tracked, $5.0B in total disclosed capital, and three unicorns already minted. That's the headline. Clover Biopharma leads the directory at $400M raised, with Tianjing Biological close behind at $380M, and the gap to the next tier is steep. Investors like Hillhouse, Lilly Asia Ventures and OrbiMed are the names showing up repeatedly, which tells you where conviction is concentrated. The global market backdrop supports the momentum, with immunology set to grow by $56.07B between 2022 and 2027 at roughly 7.5% CAGR, driven partly by China's own favorable regulatory frameworks and faster approval timelines.
Hot themes right now? Vaccine immunogenicity, immune response measurement, and live trial activity. I'd flag that the adjuvant science piece making rounds this month reflects exactly the kind of foundational R&D conversation Chinese biotechs are leaning into as they build out their pipeline differentiation. Coverage across the sector is otherwise flat, so the companies breaking through on vaccine candidates and alliance deals are the ones pulling attention. If you're trying to locate where the real funding momentum sits, this ranked list is your fastest read.
Ranked: Best Immunology companies in China
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 50 mo ago | Series C | 2019 | Dr InBev Co-Founder & Co-CEO | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 46 mo ago | Public | 2011 | Michael Yu Founder & CEO | — | 1 partnership |
| 3 | Clover Biopharma Developer of drugs to treat autoimmune, cancer and infectious diseases 67Funding top 13%Market top 25%Global top 44%Moat top 48% All 6 signals ▾Fundingtop 13% Markettop 25% Globaltop 44% Moattop 48% Newsbottom 32% Techbottom 24% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom rank vs industry peers · Fliar Intelligence Index 67/100 | $400M | 3 mo ago | Public | 2007 | — | — | — |
| 4 | Tianjing Biological Developer of immuno-oncology drugs for treating cancer and autoimmune diseases 55Funding top 21%Market top 41%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 21% Markettop 41% Moattop 48% Talentbottom 49% Globalbottom 46% Techbottom 45% Newsbottom 21% Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property rank vs industry peers · Fliar Intelligence Index 55/100 | $380M | 28 mo ago | Public | 2014 | Yan Jingwu Chairman & CEO | — | — |
| 5 | Hasten Biopharma Developer of therapeutics for cardiovascular and metabolism fields | $315M | 38 mo ago | Series D | 2020 | — | — | 1 award |
| 6 | HIBio 🦄 Developer of precision medicines for autoimmune and inflammatory diseases 57Funding top 27%Market top 38%Moat top 47%Talent bottom 49% All 6 signals ▾Fundingtop 27% Markettop 38% Moattop 47% Talentbottom 49% Globalbottom 38% Newsbottom 22% Funding: Raised $215M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Market: 44 employees (top 40% of Life Sciences) · Unicorn (valued $1.8B) rank vs industry peers · Fliar Intelligence Index 57/100 | $215M | 30 mo ago | Acquired | 2021 | Travis Murdoch Founder & CEO | — | — |
| 7 | Hutchison China MediTech Developer of immunotherapies for the treatment of cancer and immunological diseases | $215M | 52 mo ago | Public | 2005 | — | — | 1 award |
| 8 | InnoCare Developer of small molecule based therapeutics for the treatment of cancer and autoimmune disorders | $215M | 90 mo ago | Public | 2015 | Jasmine Cui Co-Founder & CEO | — | 1 award |
| 9 | BioRay Pharmaceutical 🦄 Developer of therapeutics for immunology and oncology | $215M | 42 mo ago | Acquired | 2019 | Haibin Wang CEO | — | — |
| 10 | Suzhou Connect Biopharmaceuticals Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation | $195M | 70 mo ago | Public | 2012 | Zheng Wei Co-Founder & CEO | 87 patents Therapeutic antibodies targeting IL‑4Rα and novel S1P1 receptor agonist salts | — |
| 11 | KeyMed Biosciences Developer of antibody-based therapeutics for cancer and autoimmune diseases | $190M | 48 mo ago | Public | 2016 | Bo Chen CEO | 101 patents Patents concentrated in health & consumer products | — |
| 12 | GenFleet Therapeutics Developer of drugs for treating tumors and autoimmune diseases | $166M | 54 mo ago | Public | 2017 | Jiong Lan Co-Founder & CEO | 210 patents Design and synthesis of small‑molecule kinase inhibitors, macrocycles, and antibody‑drug conjugates for oncology. | — |
| 13 | Inmagene Developer of therapeutics for immunology-related diseases | $121M | 61 mo ago | Series C | 2019 | Jonathan Wang CEO | — | — |
| 14 | Duality Biologics Developer of ADC therapeutics to treat cancer and autoimmune diseases | $120M | 61 mo ago | Public | 2020 | John Zhu Founder&Ceo | 136 patents Bispecific antibody‑drug conjugates and targeted therapeutic antibodies for oncology. | 1 job opening |
| 15 | Remegen Developer of therapies for the treatment of cancer, autoimmune and eye diseases | $100M | 75 mo ago | Public | 2008 | Jianmin Fang Co-Founder & CEO | 405 patents Therapeutic antibody‑drug conjugates and bispecific antibodies for oncology and autoimmune diseases | — |
| 16 | Pyrotech Manufacturer of therapeutics for inflammatory and oncology conditions | $97M | 25 mo ago | Series A | 2020 | TJ Deng Co-Founder & CEO | 2 patents Innovative star-shaped glass curtain wall façade modules for architectural building envelopes. | — |
| 17 | Biosion Developer of antibody-based therapeutics to treat various diseases | $76M | 38 mo ago | Series B | 2017 | Mingjiu Chen Founder & Chairman &CEO | 131 patents Therapeutic antibodies and fusion proteins for immune checkpoint and tumor antigen targeting | 1 launch |
| 18 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 1 mo ago | Series C | 2017 | Xiaohu Zhang Co-Founder & CEO | — | — |
| 19 | Worg Developer of treatments for allergic and autoimmune diseases | $57M | 45 mo ago | Series B | 2018 | — | — | — |
| 20 | Guangzhou Zhiyi Pharmaceutics Developer of second-generation probiotics | $45M | 27 mo ago | Series C | 2013 | Ye Wang CEO | — | — |
| 21 | Junshi BioPharma Provider of antibody-based therapeutics for multiple diseases | $31M | 100 mo ago | Public | 2012 | — | — | — |
| 22 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 8 mo ago | Series B | 2021 | Rongkuan Hu Founder | — | — |
| 23 | Precision Autoimmune Therapeutics Developer of therapeutics to treat autoimmune and inflammatory diseases | $21M | 49 mo ago | Seed | — | — | — | — |
| 24 | Cascade Pharmaceuticals Developer of therapeutics to treat metabolic and inflammatory diseases | $19M | 34 mo ago | Series A | 2017 | Xu Huaqiang Co-Founder & Chairman | 25 patents Small-molecule thyroid hormone receptor β agonists for metabolic and endocrine therapies | — |
| 25 | Shanghai Luoqi Biomedical Technology Developer of nano-antibody drugs for multiple ailments | $15M | 63 mo ago | Series B | 2017 | — | — | — |
| 26 | Qiyuan Biological Developer of drugs for the treatment of autoimmune diseases 22Funding top 41%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 41% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 10 mo ago | Series B | 2020 | Ding Shizhe CEO | — | — |
| 27 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 9 mo ago | Series B | 2021 | Yuxuan Wu Founder & CEO | — | — |
| 28 | Zedman Pharmaceuticals Developer of drugs for the treatment of autoimmune inflammatory diseases | $14M | 20 mo ago | Series A | 2021 | Chen Genghui CEO | — | — |
| 29 | Immuno Cure Developer of DNA vaccines and immunotherapies for multiple disorders | $12M | 35 mo ago | Series A | 2015 | Percy Cheng Co-Founder | — | — |
| 30 | Polymed Biopharmaceuticals Developer of small molecule therapeutics for cancer and autoimmune diseases | $8M | 59 mo ago | Seed | 2018 | Jason Xiang Founder & CEO | 47 patents Patents concentrated in chemistry & materials | — |
| 31 | Puyuan Biotech Developer of microbial drugs for immune diseases | $1M | 41 mo ago | Seed | — | — | — | — |
| 32 | Forward Pharma Developer of therapeutics for oncology and immunology | $1M | 35 mo ago | Series A | 2017 | Liangliang Xu CEO | — | — |
Top 12 Immunology companies in China
#1
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees$400Mraised▾
Developer of drugs to treat autoimmune, cancer, and infectious diseases. The company has developed its proprietary Trimer-Tag technology to develop novel, trimerized fusion-protein therapies. The trimerized fusion proteins have been shown to have a much better binding and therapeutic response. The company's drug pipeline include SCB-808, in a ready-for-injection prefilled syringe formulation and SCB-313 for Oncology.
- Mar 2026Post IPO$3.6M
- Apr 2024Post IPO$320.7K
- May 2023Post IPO$48.9M
- Dec 2022Post IPO$64.4M
#2
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
- May 2026Series C$50M
- Mar 2025Series B$12M
#3
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#4
Series B · Shanghai, Shanghai · founded 2021$14.1Mraised▾
Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.
- Sep 2025Series B$45M
- Nov 2023Series A$14.1M
- Feb 2022Angel—
- Series A—
#5
Series B · Hangzhou, Zhejiang · founded 2020$14.5Mraised▾
Developer of drugs for the treatment of autoimmune diseases. The lead candidate of the company includes "QY101" a non-hormonal and non-steroidal anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor for Atopic dermatitis. Other drug candidates include QY211 for psoriasis, QY301 for ulcerative colitis, Crohn's disease, and QY401 for respiratory-related indications.
- Sep 2025Series B$28M
- Aug 2022Series A$14.5M
#6
Public · Shanghai, Shanghai · founded 2014 · 318 employees$380Mraised▾
Developer of immuno-oncology drugs for treating cancer and autoimmune diseases. The company has developed an in-house platform to generate monoclonal antibodies through hybridoma and phage display technologies. The company's product line include Olamkicept used for treating ulcerative colitis, TJ202 for Multiple myeloma / Autoimmune diseases, TJ101 for pediatric growth hormone deficiency, TJ301 for Ulcerative colitis / Auto-immune disease, Enoblituzumab for T cell activation combined with tumor-killing, etc.
- Feb 2024Post IPO$69.9M
- Sep 2020Post IPO$418M
- Jun 2018Series C$220M
- Mar 2017Series B$150M
#7
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#8
HIBio 🦄Acquired · Foshan, Guangdong Province · founded 2021 · 44 employees$215Mraised▾
Developer of precision medicines for autoimmune and inflammatory diseases
- Jan 2024Series B$95M
- Nov 2022Series B$120M
#9
Series A · Beijing, Beijing · founded 2020 · 10 employees$96.9Mraised▾
Manufacturer of therapeutics for inflammatory and oncology conditions. The company develops small molecule and biologic immunomodulators to advance clinical studies and the pipeline for inflammation-related diseases as diverse as cancer, sepsis and Alzheimer’s.
- May 2024Series A—
- Jul 2023Series A$96.9M
#10
Series A · Pudong, Shanghai · founded 2021$14Mraised▾
Developer of drugs for the treatment of autoimmune inflammatory diseases. The company focuses on the development and clinical research of therapeutic drugs for multiple autoimmune inflammatory diseases related to the aryl hydrocarbon receptor (AhR) target.
- Oct 2024Series A$14M
#11
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees$535Mraised▾
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
- Aug 2022Post IPO$307.9M
- Oct 2019Post IPO$299.8M
- Apr 2018Series E$150M
- Nov 2016Series D$260M
#12
Series D · Hefei, Anhui · founded 2020 · 700 employees$315Mraised▾
Developer of therapeutics for cardiovascular and metabolism fields. The company develops a product pipeline in the field of chronic disease and age-related disease management. The company's product line includes Anidin for Cardiovascular disease and Basexin for Metabolism conditions.
- Apr 2023Series D$315M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in China
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,284 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College768
- Sun Yat-sen University577
- Huazhong University of Science and Technology478
- Sichuan University472
- Central South University429
- Immune system12→1935
- Tumor microenvironment5→900
- Cancer immunotherapy11→749
- Cancer research17→713
- Cancer8→539
- Immune system18→3166
- Cancer9→1244
- Tumor microenvironment10→1208
- Cancer research33→950
- Cancer immunotherapy5→749
- Immune system6→691
- Cancer5→349
- Tumor microenvironment1→306
- Cancer immunotherapy3→204
- Oncology2→162
Where immunology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in China
China immunology patent filing is accelerating — 531 filings from 366 assignees (2016–2025), led by Zhejiang DTRM Biopharma, Shanghai YAO YUAN Biotechnology, Versitech; annual filings 24→67.
- Zhejiang DTRM Biopharma29
- Shanghai YAO YUAN Biotechnology27
- Versitech26
- UNIV Fudan24
- Carsgen Therapeutics19
- Shanghai Birdie Biotech18
- GV20 Therapeutics17
- Xinfu Beijing Medical TECH15
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.